Brean Murray Carret & Co. Maintains a 'Sell' on Idenix Pharmaceuticals (IDIX); Hep C Pipeline Progresses, But Future Development Strategy Appears Risky

Brean Murray Carret & Co. maintains a 'Sell' on Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) price target of $3.00.

Brean analyst said, "...We do not believe that an IDX184 anchored combo is likely to succeed where GS-7977+RBV failed. Furthermore, we believe the lack of preclinical tox for durations exceeding 12 weeks is a significant hurdle to any potential acquirer given what we see as an increasing sentiment that 12 weeks of therapy may not be enough for harder to treat patients, regardless of the combination being used."

For an analyst ratings summary and ratings history on Idenix Pharmaceuticals Inc. click here. For more ratings news on Idenix Pharmaceuticals Inc. click here.

Shares of Idenix Pharmaceuticals Inc. closed at $12.29 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results